Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Oct 9;23(1):381.
doi: 10.1186/s12890-023-02682-3.

Bronchodilator reversibility testing in morbidly obese non-smokers: fluticasone/salmeterol efficacy versus salbutamol bronchodilator

Mona Ibrahim Ahmed  1 , Randa Ibrahim Ahmed  1 , Hasnaa Osama  2 , Amira Karam Khalifa  3   4 , Abdullah Ali Alshehri  5 , Gaber El-Saber Batiha  6 , Walaa A Negm  7 , Marwa Kamal  8
Affiliations

Bronchodilator reversibility testing in morbidly obese non-smokers: fluticasone/salmeterol efficacy versus salbutamol bronchodilator

Mona Ibrahim Ahmed et al. BMC Pulm Med. .

Abstract

A positive response in reversibility testing is widely used to diagnose patients with airway limitations. However, despite its simple procedure, it doesn't accurately reflect the exact airway irreversibility. This study aimed to investigate the efficacy of a bronchodilation reversibility test using salbutamol and fluticasone/salmeterol combination in obese non-smoker subjects.The study included patients without a history of obstructive lung disease or bronchodilators. A sub-classification of patients based on body mass index (BMI) was carried out into normal (< 24.9 kg/m2), overweight (25-29.9 kg/m2), and obese (BMI ≥ 30). Spirometry measurements were performed before and after salbutamol or fluticasone/salmeterol administration.The study included 415 (49.9% male) patients with a mean age of 40.92 ± 10.86 years. Obese subjects showed a high prevalence of restrictive patterns (23.4%), with non-significantly lower spirometric values compared to normal and overweight subjects (p > 0.05). The magnitude of bronchodilation, as identified by spirometry, following fluticasone/salmeterol was higher in all participants, with a significant increase in obese subjects with a p-value of 0.013, 0.002, and 0.035 for FEV1, FEV1% predicted, and FEV1/FVC, respectively.Fluticasone/salmeterol combination increases FEV1, FEV1% of predicted, and FEV1/FVC ratio than the conventional test using salbutamol inhaler, and it can be a potential candidate for assessment of airway obstruction using reversibility test, especially among the obese population.

Keywords: Bronchodilators; Obese, fluticasone/salmeterol; Reversibility test; Salbutamol; Spirometry.

PubMed Disclaimer

Conflict of interest statement

Authors have no conflict of interest to declare.

Figures

Fig. 1
Fig. 1
Mean change in spirometric results; (a) FEV1 (L) and (b) FEV1% of predicted (FEV1%) within the study groups
See this image and copyright information in PMC

Comment in

References

    1. Richter DC, Joubert JR, Nell H, Schuurmans MM, Irusen EM. Diagnostic value of post-bronchodilator pulmonary function testing to distinguish between stable, moderate to severe COPD and asthma. Int J Chronic Obstr Pulm Dis. 2008;3(4):693. - PMC - PubMed
    1. Levy ML, Quanjer PH, Rachel B, Cooper BG, Holmes S, Small IR. Diagnostic spirometry in primary care: proposed standards for general practice compliant with american thoracic Society and European Respiratory Society recommendations. Prim Care Respiratory J. 2009;18(3):130–47. doi: 10.4104/pcrj.2009.00054. - DOI - PMC - PubMed
    1. Nurulrahman M, Damailia R, Achmad S. Pengaruh Penggunaan Masker terhadap Gangguan Fungsi Paru dengan Mengukur FEV1, FVC dan Rasio FEV1/FVC pada Pekerja Industri Pupuk NPK di Cikampek. Prosiding Pendidikan Dokter 2020:210–5.
    1. Ioachimescu OC, Ramos JA, Hoffman M, McCarthy K, Stoller JK. Assessing bronchodilator response by changes in per cent predicted forced expiratory volume in one second. J Investig Med. 2021;69(5):1027–34. doi: 10.1136/jim-2020-001663. - DOI - PMC - PubMed
    1. Carpaij OA, van den Berge M. The asthma–obesity relationship: underlying mechanisms and treatment implications. Curr Opin Pulm Med. 2018;24(1):42–9. doi: 10.1097/MCP.0000000000000446. - DOI - PubMed

LinkOut - more resources